Therapeutic manipulation of myosin can abate the effects of MYBPC3 mutations in hypertrophic cardiomyopathy.
Mutations in MYBPC3 disrupt myosin states of relaxation, and manipulating myosin therapeutically abates the effects of MYBPC3 mutations.
Toepfer et al. (Wed,) studied this question.